Year: 2025
Type: article
Abstract: Globally, respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infection (LRTI) in children under five. 1 In 2019, children under five experienced ~33 million RSV infections, leading to >100,000 deaths; more than 95% of these occurred in low-and middle-income countries (LMICs). 1 Prevention of infant RSVassociated severe lower respiratory tract infection (RSV-LRTI) is therefore critical.Immune protection for infants is possible through two mechanisms: infant monoclonal antibody administration (e.g., nirvesimab, available in the US but with very limited availability in LMICs) or active vaccination in pregnancy, which provides passive immunization to infants through transplacental antibody transfer.Patients and healthcare providers who have lived and worked entirely in the era of effective vaccines -and robust public health programs to administer them -may not have directly witnessed the benefit of vaccines to prevent infant morbidity and mortality.As a result, uptake of vaccines may depend more on patient and provider perception of vaccine safety than perception of vaccine efficacy.
Source: Obstetrics and Gynecology
Institutions: Brown University, Massachusetts General Hospital
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4406009905